Vor Biopharma (VOR) Competitors

$16.72 +0.64 (+4.00%)

As of 03:28 PM Eastern

VOR vs. GPCR, ARQT, DNLI, GMTX, and DYN

Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Denali Therapeutics (DNLI), Gemini Therapeutics (GMTX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does Vor Biopharma compare to Structure Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Structure Therapeutics (NASDAQ:GPCR) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its share price is 231% less volatile than the S&P 500.

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vor Biopharma presently has a consensus price target of $50.56, indicating a potential upside of 202.31%. Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 180.13%. Given Vor Biopharma's higher possible upside, research analysts plainly believe Vor Biopharma is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.75
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

In the previous week, Structure Therapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 7 mentions for Structure Therapeutics and 2 mentions for Vor Biopharma. Structure Therapeutics' average media sentiment score of 1.06 beat Vor Biopharma's score of 0.77 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.79	N/A

Vor Biopharma's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Structure Therapeutics	N/A	-25.90%	-24.54%

Summary

Structure Therapeutics beats Vor Biopharma on 7 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Vor Biopharma (NASDAQ:VOR) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Vor Biopharma presently has a consensus target price of $50.56, indicating a potential upside of 202.31%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 62.72%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.75
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vor Biopharma has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Vor Biopharma has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Vor Biopharma's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Arcutis Biotherapeutics	-0.57%	-1.47%	-0.62%

97.3% of Vor Biopharma shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vor Biopharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Arcutis Biotherapeutics	$376.07M	6.95	-$16.14M	-$0.14	N/A

In the previous week, Arcutis Biotherapeutics had 33 more articles in the media than Vor Biopharma. MarketBeat recorded 35 mentions for Arcutis Biotherapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.77 beat Arcutis Biotherapeutics' score of 0.29 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Vor Biopharma beats Arcutis Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Vor Biopharma compare to Denali Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Denali Therapeutics (NASDAQ:DNLI) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vor Biopharma currently has a consensus target price of $50.56, suggesting a potential upside of 202.31%. Denali Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 73.17%. Given Vor Biopharma's higher probable upside, equities research analysts clearly believe Vor Biopharma is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.75
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

In the previous week, Denali Therapeutics had 11 more articles in the media than Vor Biopharma. MarketBeat recorded 13 mentions for Denali Therapeutics and 2 mentions for Vor Biopharma. Denali Therapeutics' average media sentiment score of 0.93 beat Vor Biopharma's score of 0.77 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.97	N/A

Vor Biopharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Denali Therapeutics	N/A	-50.13%	-44.20%

Summary

Vor Biopharma beats Denali Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Gemini Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Gemini Therapeutics (NASDAQ:GMTX) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Vor Biopharma has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500.

Vor Biopharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Vor Biopharma had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Vor Biopharma and 1 mentions for Gemini Therapeutics. Vor Biopharma's average media sentiment score of 0.77 beat Gemini Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vor Biopharma currently has a consensus target price of $50.56, indicating a potential upside of 202.31%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.75
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Vor Biopharma beats Gemini Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Dyne Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Dyne Therapeutics (NASDAQ:DYN) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Dyne Therapeutics	N/A	-61.46%	-50.94%

Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

In the previous week, Dyne Therapeutics had 12 more articles in the media than Vor Biopharma. MarketBeat recorded 14 mentions for Dyne Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.77 beat Dyne Therapeutics' score of 0.51 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	5 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma presently has a consensus target price of $50.56, indicating a potential upside of 202.31%. Dyne Therapeutics has a consensus target price of $35.14, indicating a potential upside of 98.32%. Given Vor Biopharma's higher possible upside, research analysts clearly believe Vor Biopharma is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.75
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A

Summary

Vor Biopharma beats Dyne Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$914.34M	$361.35M	$4.23B	$12.26B
Dividend Yield	N/A	N/A	5.92%	5.24%
P/E Ratio	-0.04	N/A	23.61	27.20
Price / Sales	N/A	394.28	185.14	64.32
Price / Cash	N/A	N/A	52.59	53.97
Price / Book	N/A	2.79	39.98	6.83
Net Income	N/A	-$81.71M	$114.66M	$332.87M
7 Day Performance	N/A	N/A	-1.13%	0.16%
1 Month Performance	6.25%	6.31%	4.73%	7.17%
1 Year Performance	N/A	N/A	20.06%	40.61%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	3.3864 of 5 stars	$16.72 +4.0%	$50.56 +202.3%	N/A	$914.34M	N/A	N/A	140
GPCR Structure Therapeutics	2.8234 of 5 stars	$42.21 +1.8%	$109.25 +158.8%	+47.5%	$2.99B	N/A	N/A	136	News Coverage Positive News Gap Down
ARQT Arcutis Biotherapeutics	3.2715 of 5 stars	$23.35 +0.6%	$34.00 +45.6%	+51.4%	$2.92B	$376.07M	N/A	150	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
DNLI Denali Therapeutics	3.0401 of 5 stars	$18.30 -2.2%	$35.00 +91.3%	+38.2%	$2.90B	$330.53M	N/A	430	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
GMTX Gemini Therapeutics	N/A	$66.91 +1.5%	N/A	+61.2%	$2.90B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. GPCR, ARQT, DNLI, GMTX, and DYN

How does Vor Biopharma compare to Structure Therapeutics?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Vor Biopharma compare to Denali Therapeutics?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. GPCR, ARQT, DNLI, GMTX, and DYN

How does Vor Biopharma compare to Structure Therapeutics?

Which has more volatility and risk, VOR or GPCR?

Do insiders & institutionals have more ownership in VOR or GPCR?

Do analysts rate VOR or GPCR?

Does the media prefer VOR or GPCR?

Which has higher valuation and earnings, VOR or GPCR?

Is VOR or GPCR more profitable?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Do analysts recommend VOR or ARQT?

Which has more risk and volatility, VOR or ARQT?

Is VOR or ARQT more profitable?

Do institutionals & insiders have more ownership in VOR or ARQT?

Which has stronger valuation & earnings, VOR or ARQT?

Does the media prefer VOR or ARQT?

Summary

How does Vor Biopharma compare to Denali Therapeutics?

Do insiders & institutionals hold more shares of VOR or DNLI?

Do analysts rate VOR or DNLI?

Which has more risk & volatility, VOR or DNLI?

Does the media refer more to VOR or DNLI?

Which has preferable valuation and earnings, VOR or DNLI?

Is VOR or DNLI more profitable?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Which has stronger earnings and valuation, VOR or GMTX?

Which has more risk & volatility, VOR or GMTX?

Is VOR or GMTX more profitable?

Does the media refer more to VOR or GMTX?

Do institutionals and insiders believe in VOR or GMTX?

Do analysts recommend VOR or GMTX?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Do institutionals & insiders believe in VOR or DYN?

Is VOR or DYN more profitable?

Which has more risk and volatility, VOR or DYN?

Does the media prefer VOR or DYN?

Do analysts prefer VOR or DYN?

Which has stronger valuation and earnings, VOR or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools